Septerna, Inc. (SEPN) Quick Ratio
- Quick ratio · latest quarter: Value 4.85×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 4.85× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $384.48M ÷ $79.32M ≈ 4.85× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 384.48M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 79.32M USD | Liabilities, Current |
| Cash and equivalents | 84.66M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 287.66M USD | Marketable Securities, Current |
| Customer receivables | 12.16M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $384.48M | $79.32M | $84.66M | $287.66M | $12.16M | (m) | 4.85× |
| 2026-03-31 | $358.24M | $78.17M | $71.61M | $275.80M | $10.84M | (m) | 4.58× |
| 2025-12-31 | $401.44M | $86.93M | $120.72M | $270.37M | $10.36M | (m) | 4.62× |
| 2025-09-30 | $482.99M | $75.28M | $319.99M | $154.36M | $8.64M | (m) | 6.42× |
| 2025-06-30 | $326.71M | $15.13M | $189.31M | $137.25M | $151.00K | (m) | 21.60× |
| 2025-03-31 | $336.25M | $10.64M | $210.04M | $125.96M | $250.00K | (m) | 31.61× |
| 2024-12-31 | $351.09M | $12.85M | $238.20M | $112.73M | $171.00K | (m) | 27.32× |
| 2024-09-30 | $130.74M | $13.23M | $88.24M | $42.29M | $210.00K | (m) | 9.88× |
| 2024-06-30 | (m) | (m) | $131.17M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $81.34M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $6.91M | $88.48M | (m) | $151.00K | (m) | (m) |
| 2023-09-30 | (m) | (m) | $98.52M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |